Victrex plc (LON:VCT)
London flag London · Delayed Price · Currency is GBP · Price in GBX
932.00
-10.00 (-1.06%)
Oct 14, 2026, 4:37 PM GMT

Victrex Earnings Call Transcripts

Fiscal Year 2026

  • CMD 2026

    A comprehensive transformation is underway, focusing on execution, cost discipline, and commercial rigor to unlock sustainable profit growth. Financial targets include mid-single-digit revenue CAGR, margin recovery, and £250m free cash flow over five years, with at least 75% returned to shareholders.

  • H1 saw modest revenue growth and strong cash flow, but margins and profits declined due to price and mix pressures. A major China plant impairment and restructuring are underway, with a new decentralized model and profit improvement plan expected to drive better performance in H2 and beyond.

Fiscal Year 2025

  • FY 2025 saw strong volume growth but limited revenue gains due to currency and mix, with profit down and robust cash conversion. A profit improvement plan aims for GBP 10 million in savings, while FY 2026 guidance targets moderate growth, margin stability, and continued CapEx discipline.

  • Q3 saw 8% volume growth but a 3% revenue decline due to adverse mix and medical weakness. Full-year volume guidance remains high single digits, with currency and medical spine headwinds impacting outlook. CEO transition and China facility progress highlighted.

  • H1 2025 saw 16% volume growth and strong cash conversion, but gross margin and ASP declined due to mix and China ramp-up costs. Upgraded full-year volume guidance to high single digits, with medical and Magma programs expected to drive future growth.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022